ClinicalTrials.gov
public full text
Public Domain
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The overall objective is to investigate the safety, tolerability and effect on insulin-like growth factor-1 (IGF-1), inflammatory and fibrotic biomarkers of TEPEZZA (teprotumumab-trbw, HZN-001), a fully human monoclonal antibody (mAb) inhibitor of the IGF-1 receptor (IGF-1R), administered once every 3 weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)#812991
- Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)#805138
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.#900779
- Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis#1102269
- Associations of Blood Soluble Fas and IGF-I with Risk of Hemorrhagic Stroke: The Circulatory Risk Communities Study (CIRCS).#214252
Record · ID 966833
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive